Neuropsychopharmacology reports · 2026
Hydrogen Gas Therapy in Schizophrenia: Potential Neuroprotective Effects From an Animal Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Miyake Nobumi, Haga Toshiaki, Hirano Shin-Ichi, Ichikawa Yusuke, Oguchi Yoshiyo, Ando Kumiko
Аннотация
AIMS: Oxidative stress has recently emerged as a key factor in the pathophysiology of schizophrenia. This study investigated whether inhalation therapy with hydrogen gas, a selective antioxidant, could reduce oxidative stress and improve behavioral outcomes in an MK-801-induced schizophrenia-like mouse model.
METHODS: Six-week-old male C57BL/6 mice received chronic intraperitoneal injections of MK-801 (0.5 mg/kg) or saline for 4 weeks. A third group received MK-801 followed by hydrogen gas inhalation therapy. Behavioral assessments included the open-field test (OFT) to evaluate hyperactivity as an indicator of positive symptoms and the prepulse inhibition (PPI) test to assess cognitive dysfunction. Oxidative stress was evaluated by measuring whole-brain hydroxyl radical antioxidant capacity (HORAC) and total antioxidant capacity (TAC).
RESULTS: MK-801-treated mice exhibited significant hyperactivity in the OFT and a trend toward impaired PPI, confirming the schizophrenia-like phenotype. Hydrogen gas treatment did not produce significant improvements. MK-801 administration significantly reduced HORAC levels, whereas hydrogen gas therapy markedly restored them. No significant differences in TAC were observed among the groups.
CONCLUSION: These findings suggest that hydrogen gas therapy does not significantly ameliorate behavioral abnormalities in the MK-801-induced schizophrenia-like mouse model but exerts beneficial antioxidant effects. Future studies should evaluate hydrogen gas as an adjunctive therapy and further assess its efficacy and safety in clinical settings.
METHODS: Six-week-old male C57BL/6 mice received chronic intraperitoneal injections of MK-801 (0.5 mg/kg) or saline for 4 weeks. A third group received MK-801 followed by hydrogen gas inhalation therapy. Behavioral assessments included the open-field test (OFT) to evaluate hyperactivity as an indicator of positive symptoms and the prepulse inhibition (PPI) test to assess cognitive dysfunction. Oxidative stress was evaluated by measuring whole-brain hydroxyl radical antioxidant capacity (HORAC) and total antioxidant capacity (TAC).
RESULTS: MK-801-treated mice exhibited significant hyperactivity in the OFT and a trend toward impaired PPI, confirming the schizophrenia-like phenotype. Hydrogen gas treatment did not produce significant improvements. MK-801 administration significantly reduced HORAC levels, whereas hydrogen gas therapy markedly restored them. No significant differences in TAC were observed among the groups.
CONCLUSION: These findings suggest that hydrogen gas therapy does not significantly ameliorate behavioral abnormalities in the MK-801-induced schizophrenia-like mouse model but exerts beneficial antioxidant effects. Future studies should evaluate hydrogen gas as an adjunctive therapy and further assess its efficacy and safety in clinical settings.